OMS 405Alternative Names: OMS 403; OMS405
Latest Information Update: 15 Nov 2016
At a glance
- Originator Omeros Corporation
- Developer New York State Psychiatric Institute; Omeros Corporation
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Opioid abuse; Smoking withdrawal
- Preclinical Alcoholism